Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avillion LLP

http://avillionllp.com

Latest From Avillion LLP

Bigger Money: Private Equity Grabs European VC

Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?

Business Strategies Financing

Carlyle Bets Big On Late-Stage Biotech With Abingworth Buy

Tapping into Abingworth’s pioneering clinical co-development model, the private equity behemoth is using that experience to form Launch Therapeutics which will seek to partner with biotech and biopharma on "best‐in‐class, late‐stage clinical assets [and] bring life‐saving therapies to market better, faster and cheaper."

M & A Financing

Hengrui Takes Focused Approach Amid China Inc's Global Drive

China’s largest innovative domestic drug maker will only take global those products that play into its strengths, chairman Piaoyang Sun declares.

China Business Strategies

AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal

Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.

Respiratory Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • Avillion Group
    • Bond Avillion 2 Development LP
UsernamePublicRestriction

Register